Annual Statements Open main menu

SideChannel, Inc. - Quarter Report: 2022 March (Form 10-Q)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark one)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT

 

For the transition period from ___________ to ___________

 

Commission File No. 000-28745

 

 

Cipherloc Corporation

(Exact name of registrant as specified in its charter)

 

Delaware   86-0837077
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

6836 Bee Cave Rd, Bldg. 1, S#279

Austin, TX

  78746
(Address of principal executive offices)   (Zip Code)

 

(512) 337-3728

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer Accelerated filer
  Non-Accelerated filer Smaller reporting company
      Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes ☐ No

 

As of May 13, 2022, the registrant had 87,560,647 shares of common stock outstanding.

 

 

 

 

 

 

CIPHERLOC CORPORATION

INDEX TO FORM 10-Q FILING

FOR THE THREE AND SIX MONTHS ENDED March 31, 2022 and 2021

TABLE OF CONTENTS

 

  PAGE
   
PART I - FINANCIAL INFORMATION  
   
Item 1. Financial Statements (Unaudited) 3
  Balance Sheets as of March 31, 2022, and September 30, 2021 3
  Statements of Operations for the three and six months ended March 31, 2022, and 2021 4
  Statements of Cash Flows for the six months ended March 31, 2022, and 2021 5
  Statement of Stockholders’ Equity for the three and six months ended March 31, 2022, and 2021 6
  Notes to Financial Statements 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 13
Item 3 Quantitative and Qualitative Disclosures About Market Risk 15
Item 4. Controls and Procedures 15
     
PART II - OTHER INFORMATION  
   
Item 1. Legal Proceedings 16
Item 1A. Risk Factors 16
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 17
Item 3. Defaults Upon Senior Securities 17
Item 4. Mining Safety Disclosures 17
Item 5 Other Information 17
Item 6. Exhibits 17
  Signatures 18

 

2
Table of Contents

 

PART I

 

FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

CIPHERLOC CORPORATION

CONDENSED BALANCE SHEETS

 

   March 31, 2022   September 30, 2021 
   (UNAUDITED)     
ASSETS          
Current assets          
Cash  $4,390,059   $5,783,994 
Deferred costs   180,000    180,000 
Prepaid expenses   143,208    279,832 
Total current assets   4,713,267    6,243,826 
           
Deferred costs   420,000    510,000 
Total assets  $5,133,267   $6,753,826 
           
LIABILITIES & STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable and accrued liabilities  $433,710   $1,462,732 
Accrued compensation       25,000 
Total current liabilities   433,710    1,487,732 
           
Total liabilities   433,710    1,487,732 
           
Commitments and contingencies   -      
           
Stockholders’ equity          
Common stock, $0.001 par value, 681,000,000 shares authorized; 87,560,647 and 82,927,311 shares outstanding; and 100,975,461 and 96,342,125 issued as of March 31, 2022, and September 30, 2021, respectively   100,975    96,342 
Treasury stock, at cost, 13,414,814 and 13,414,814 shares as of March 31, 2022, and September 30, 2021, respectively   (590,000)   (590,000)
Additional paid-in capital   78,171,578    77,290,643 
Accumulated deficit   (72,982,996)   (71,530,891)
Total stockholders’ equity   4,699,557    5,266,094 
Total liabilities and stockholders’ equity  $5,133,267   $6,753,826 

 

See accompanying notes to these unaudited condensed financial statements.

 

3
Table of Contents

 

CIPHERLOC CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   2022   2021   2022   2021 
   Three Months Ended   Six Months Ended 
   March 31,   March 31, 
   2022   2021   2022   2021 
Revenues  $251   $6,667   $251   $15,417 
Cost of revenues                
Gross profit   251    6,667    251    15,417 
                     
Operating expenses                    
General and administrative   607,014    889,172    1,076,030    1,550,864 
Selling and marketing   52,375    31,250    105,768    56,250 
Research and development   140,919    175,083    270,558    296,876 
Total operating expenses   800,308    1,095,505    1,452,356    1,903,990 
Operating loss   (800,057)   (1,088,838)   (1,452,105)   (1,888,573)
                     
Net loss  $(800,057)  $(1,088,838)  $(1,452,105)  $(1,888,573)
                     
Net loss per common share – basic and diluted  $(0.01)  $(0.04)  $(0.02)  $(0.07)
                     
Weighted average common shares outstanding – basic and diluted   84,993,489    27,774,609    83,949,047    27,574,365 

 

See accompanying notes to these unaudited condensed financial statements.

 

4
Table of Contents

 

CIPHERLOC CORPORATION

STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   2022   2021 
   Six Months Ended 
   March 31, 
   2022   2021 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(1,452,105)  $(1,888,573)
Adjustments to reconcile net loss to net cash flows used in operating activities:          
Amortization   90,000     
Stock-based compensation   51,568    79,655 
Changes in operating assets and liabilities:          
Prepaid expenses and other   136,624    342,544 
Accounts payable and accrued liabilities   (220,022)   374,091 
Accrued compensation       208,750 
Deferred revenue       (15,417)
Net cash used in operating activities   (1,393,935)   (898,950)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchases of fixed assets        
Net cash used in investing activities        
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Purchase of treasury stock       (40,000)
Purchase of preferred stock       (10,000)
Proceeds from the issuance of common stock, net of costs       5,497,964 
Net cash provided by financing activities       5,447,964 
           
(DECREASE) INCREASE IN CASH   (1,393,935)   4,549,014 
CASH, BEGINNING OF PERIOD   5,783,994    1,079,839 
CASH, END OF PERIOD  $4,390,059   $5,628,853 
           
NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Shares issued for services, previously in accrued expenses  $834,000   $ 

 

See accompanying notes to these unaudited condensed financial statements.

 

5
Table of Contents

 

CIPHERLOC CORPORATION

STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(UNAUDITED)

 

For the Six Months ended March 31, 2022  Shares   Amount   Stock   Capital   Deficit   Equity 
     Common Stock   Treasury   Additional Paid-in    Accumulated   Stockholders’ 
For the Six Months ended March 31, 2022    Shares   Amount   Stock   Capital   Deficit   Equity 
Balance at September 30, 2021  -  96,342,125   $96,342   $(590,000)  $77,290,643   $(71,530,891)  $5,266,094 
Options issued to directors & employees                 51,568        51,568 
Shares issued for services  -  4,633,336    4,633        829,367        834,000 
Net loss                      (1,452,105)  $(1,452,105)
Balance at March 31, 2022  -  100,975,461   $100,975   $(590,000)  $78,171,578   $(72,982,996)  $4,699,557 

 

    Shares   Amount   Stock   Capital   Deficit   Equity 
     Common Stock   Treasury   Additional Paid-in    Accumulated   Stockholders’ 
For the Three Months ended March 31, 2022,   Shares   Amount    Stock   Capital   Deficit   Equity 
Balance at December 31, 2021 -   96,342,125   $96,342   $(590,000)  $77,313,204   $(72,182,939)  $4,636,607 
Options issued to directors & employees                 29,007        29,007 
Shares issued for services -   4,633,336    4,633        829,367        834,000 
Net loss -                    (800,057)  $(800,057)
Balance at March 31, 2022 -   100,975,461   $100,975   $(590,000)  $78,171,578   $(72,982,996)  $4,699,557 

 

  Shares   Amount   Shares   Amount   Stock   Capital   Deficit   Equity 
   Preferred Stock   Common Stock   Treasury   Additional Paid-in    Accumulated   Stockholders’ 
For the Six Months ended March 31, 2021  Shares   Amount   Shares   Amount   Stock   Capital   Deficit   Equity 
Balance at September 30, 2020   1,000,000   $10,000    40,792,510   $40,792   $(550,000)  $68,787,854   $(68,426,608)  $(137,962)
Options issued to directors & employees                       79,655        79,655 
Preferred and treasury shares acquired   (1,000,000)   (10,000)           (40,000)           (50,000)
Issuance of common stock, net of issuance costs           35,757,942    35,758        5,462,206        5,497,964 
Net loss                           (1,888,573)  $(1,888,573)
Balance at March 31, 2021      $    76,550,452   $76,550   $(590,000)  $74,329,715   $(70,315,181)  $3,501,084 

 

    Preferred Stock     Common Stock     Treasury     Additional Paid-in      Accumulated     Stockholders’  
For the Three Months ended March 31, 2021,   Shares     Amount     Shares     Amount      Stock     Capital     Deficit     Equity  
Balance at December 31, 2020         $       40,792,510     $ 40,792     $ (590,000 )   $ 68,828,879     $ (69,226,343 )   $ (946,672 )
Options issued to directors & employees                                     38,630             38,630  
Issuance of common stock, net of issuance costs                 35,757,942       35,758             5,462,206             5,497,964  
Net loss                                           (1,088,838 )   $ (1,088,838 )
Balance at March 31, 2021         $       76,550,452     $ 76,550     $ (590,000 )   $ 74,329,715     $ (70,315,181 )   $ 3,501,084  

 

See accompanying notes to these unaudited condensed financial statements.

 

6
Table of Contents

 

CIPHERLOC CORPORATION

NOTES TO FINANCIAL STATEMENTS

FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2022, AND 2021

(Unaudited)

 

NOTE 1 - DESCRIPTION OF BUSINESS

 

Cipherloc Corporation (the “Company” or “Cipherloc”) was incorporated in the State of Texas on June 22, 1953, under the name “American Mortgage Company.” Effective August 27, 2014, the Company changed its name to “Cipherloc Corporation.” Prior to September 30, 2021, the Company was a Texas corporation. The Company became a Delaware corporation effective September 30, 2021.

 

The Company’s headquarters is located at 6836 Bee Cave Road, Building 1, Suite279, Austin, Texas 78746. The Company’s website is www.cipherloc.net.

 

NOTE 2 - BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS

 

The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The accompanying interim unaudited financial statements have been prepared in accordance with U.S. GAAP for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In the Company’s opinion, it has included all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation.

 

The Company’s operating results for the six months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the entire fiscal year ending September 30, 2022. The Company has omitted notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the fiscal year ended September 30, 2021. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended September 30, 2021, included within the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission.

 

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The Company prepares its financial statements in accordance with U.S. GAAP. Significant accounting policies are as follows:

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with a maturity at the time of purchase of three months or less to be cash equivalents. At March 31, 2022, the Company’s cash included cash on hand and cash in the bank. The balance of such accounts, at times, may exceed federally insured limits, as guaranteed by the Federal Deposit Insurance Corporation (“FDIC”). The FDIC insures these deposits up to $250,000. As of March 31, 2022, $4,140,059 of the Company’s cash balance was uninsured. The Company has not experienced any losses of uninsured cash.

 

Basic and Diluted Net Loss per Common Share

 

The Company’s computes its basic loss per share by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding during the reporting period. The weighted average number of shares is calculated by taking the number of shares outstanding and weighting that number by the amount of time that the applicable shares were outstanding. Diluted earnings per share reflects the potential dilution that could occur if vested stock options, warrants, and other commitments of the Company to issue common stock were exercised, resulting in the issuance of common stock that would share in the earnings of the Company. As of March 31, 2022, the Company had no shares of preferred stock outstanding.

 

7
Table of Contents

 

The Company’s diluted loss per share was the same as basic loss per share for the periods in which the Company incurred net losses since the inclusion of potential common stock equivalents would be anti-dilutive due to the net loss. For the three and six month periods ended March 31, 2022, the Company excluded warrants to purchase 79,461,481 shares of its common stock, and 2,000,001 shares of its common stock issued pursuant to restricted stock units from the calculation of diluted loss per share because the effect would be anti-dilutive. During the three and six months ended March 31, 2021, the Company excluded warrants to purchase 60,364,253 shares of common stock and stock options to purchase 699,999 shares of common stock from the calculation of diluted loss per share because their effect would be anti-dilutive .

 

Research and Development and Software Development Costs

 

The Company expenses all research and development costs, including patent and software development costs. The research and development expenses incurred by the Company for the three months ended March 31, 2022 and 2021 were $140,919 and $175,083, respectively which is a 19.5% decrease. The research and development costs incurred by the Company for the six months ended March 31, 2022 and 2021 were $270,558 and $296,876, respectively.

 

Revenue Recognition

 

The Company recognizes revenues in accordance with the provisions of ASC 606, “Revenue from Contracts with Customers,” and a series of amendments, issued by the Financial Accounting Standards Board (“FASB”).

 

Central to the Company’s revenue recognition guidance is a five-step revenue recognition model that requires reporting entities to:

 

1. Identify the contract,
2. Identify the performance obligations of the contract,
3. Determine the transaction price of the contract,
4. Allocate the transaction price to the performance obligations, and
5. Recognize revenue.

 

The Company accounts for a promise to provide a customer with a right to access the Company’s intellectual property as a performance obligation satisfied over time, because the customer will simultaneously receive and consume the benefit from access to the Company’s intellectual property as the performance occurs.

 

Software License Agreements

 

During the fiscal year ended September 30, 2019, the Company entered into an agreement with SoundFi LLC (“SoundFi”). The SoundFi agreement provides for a one-year term that automatically renews for subsequent one-year periods unless otherwise terminated by either party. The Company received a payment of $25,000 from SoundFi during the fiscal year ended September 30, 2020. However, the Company has not yet received any payments from SoundFi in the current fiscal year and is uncertain if there will be any such payments.

 

The Company executed a software licensing agreement with Castle Shield Holdings, LLC (“Castle Shield”) during the fiscal year ended September 30, 2020. That agreement includes an auto-renewing annual term. The Company received a $10,000 payment from Castle Shield during the fiscal year ended September 30, 2020, but did not receive any payments from Castle Shield during the fiscal year ended September 30, 2021. However, the Company did receive payments totaling $15,417 from Castle Shield during the six months ended March 31, 2021. The Company recognized $251 in licensing revenues from Castle Shield during the six months ended March 31, 2022.

 

8
Table of Contents

 

Recent Accounting Pronouncements

 

The Financial Accounting Standards Board (“FASB”) issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the ASC. There have been several ASUs to date that amend the original text of the ASCs. Other than those discussed below, the Company believes those ASUs issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company or (iv) are not expected to have a significant impact on the Company.

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This guidance removes certain exceptions to the general principles in Topic 740 and enhances and simplifies various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company adopted ASU 2019-12 on October 1, 2021, and the adoption of this update did not have a material impact on the Company’s financial position, results of operations and cash flows.

 

In January 2020, the FASB issued guidance to clarify certain interactions between the guidance to account for equity securities, the guidance to account for investments under the equity method of accounting, and the guidance to account for derivatives and hedging. The new guidance clarifies the application of measurement alternatives and the accounting for certain forward contracts and purchased options to acquire investments. The Company adopted this guidance on October 1, 2021, and the adoption of this update did not have a material impact on the Company’s financial position, results of operations and cash flows.

 

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). The new ASU addresses an issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This amendment is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted.

 

9
Table of Contents

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses, which requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The guidance is effective for fiscal years beginning after December 15, 2019. In November 2019, the FASB issued ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), which pushes back the effective date for public business entities that are smaller reporting companies, as defined by the SEC, to fiscal years beginning after December 15, 2022. Early adoption is permitted.

 

In November 2021, the FASB issued guidance to increase the transparency of government assistance received by an entity by requiring disclosures relating to accounting policy, nature of the assistance, and the effect of the assistance on the financial statements. The Company is required to adopt the guidance in the first quarter of its fiscal 2023. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its financial statements.

 

[In August 2020, the FASB issued ASU 2020-06—Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and edging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) to simplify the accounting for convertible instruments by removing certain separation models in Subtopic 470- 20, Debt with Conversion and Other Options, for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost and a convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments typically will be closer to the coupon interest rate when applying the guidance in Topic 835, Interest. The amendments in ASU 2020-06 provide financial statement users with a simpler and more consistent starting point to perform analyses across entities. The amendments also improve the operability of the guidance and reduce, to a large extent, the complexities in the accounting for convertible instruments and the difficulties with the interpretation and application of the relevant guidance.

 

Additionally, for convertible debt instruments with substantial premiums accounted for as paid-in capital, amendments in ASU 2020-06 added disclosures about (1) the fair value amount and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in capital.

 

The amendments in ASU 2020-06 are effective for public business entities, excluding entities eligible to be smaller reporting companies, as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted ASU 2020-06 on October 1, 2021, and the adoption of this update did not have a material impact on the Company’s financial position, results of operations and cash flows.

 

10
Table of Contents

 

NOTE 4– COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is currently not involved in any litigation that it believes could have a material adverse effect on its financial condition or results of operations.

 

In December 2017, Robert LeBlanc filed a petition against the Company and Michael De La Garza, the Company’s former Chief Executive Officer and President, in the 20th Judicial District for Hays County, Texas (Cause No. 18-0005). Mr. LeBlanc claims that he is a former consultant, employee, and/or officer of the Company, Mr. LeBlanc’s petition (which has been amended) alleges causes of action against the Company for alleged violation of the Texas Securities Act, common law fraud against Mr. De La Garza; breach of fiduciary duty against Mr. De La Garza; breach of contract; as well as declaratory relief. Mr. LeBlanc seeks damages exceeding $1,000,000, but less than $10,000,000. The Company believes that Mr. LeBlanc was fully compensated for his services, and that his claims are without merit. Mr. LeBlanc is also asserting a claim of partial ownership of certain of the Company’s patents, which the Company believes is without merit. The Company believes it has meritorious defenses to Mr. LeBlanc’s allegations, and the Company intends to continue to vigorously defend against the litigation.

 

In April 2020, Eric Marquez, the former Secretary/Treasurer and Chief Financial Officer of the Company, and certain other plaintiffs filed a lawsuit against the Company and Michael De La Garza, the Company’s former Chief Executive Officer and President, in the 20th Judicial District for Hays County, Texas (Cause No. 20-0818). The lawsuit alleges causes of action for fraud against Mr. De La Garza (for misrepresentations allegedly made by Mr. De La Garza); breach of contract, for alleged breaches of Mr. Marquez’s alleged oral employment agreement, which Mr. Marquez claims required the Company pay him cash and shares of stock; unjust enrichment; quantum meruit; and rescission of certain stock purchases made by certain of the plaintiffs, as well as requests for declaratory relief. Damages sought exceed $1,000,000. The Company believes it has made all required payments and delivered the stock to the plaintiffs. The case is currently being defended by the Company. The Company believes it has meritorious defenses to the allegations, and the Company intends to continue to vigorously defend against the litigation.

 

Leases

 

As of March 31, 2022, the Company had no financial obligations for facility lease agreements, except as set forth below.

 

Prior to December 1, 2021, Tom Wilkinson, the Company’s Chairman of the Board of Directors, provided the Company with the use of office space that he rents, located at 6836 Bee Caves Road, Building 1, Suite 279, Austin, TX 78746, for its corporate headquarters. As of December 1, 2021, the Company entered into a month-to-month lease agreement for this office space with Nolen & Associates, under which the Company pays Nolen & Associates $500 per month in rent.

 

The Company’s rent expense totaled $1,641 and $2,141 for the three and six months ended March 31, 2022, and $97,910 and $136,188 for the three and six months ended March 31, 2021, respectively.

 

11
Table of Contents

 

NOTE 5 – DEBT

 

On April 6, 2020, to supplement its cash balances, the Company submitted an application for a $365,430 loan under the Paycheck Protection Program (“PPP”) sponsored by the U.S. Small Business Administration (the “SBA Loan”). On April 12, 2020, the SBA Loan application was approved, and the Company received the loan proceeds on April 22, 2020. The SBA Loan had an interest rate of 1% and was scheduled to mature on April 12, 2022.

 

On January 29, 2021, the Company filed for partial forgiveness of $192,052 of the SBA Loan, which was approved on June 11, 2021. The Company’s reductions in staff that occurred in 2020 prevented the Company from qualifying for full forgiveness of the principal balance of the SBA Loan.

 

On April 15, 2021, the Company placed the full $365,430 principal balance of the SBA Loan, plus an additional $1,000, in an escrow account. Upon approval of the partial SBA Loan forgiveness, the Company paid the remaining balance of the SBA Loan, using funds in the escrow account. The Company transferred the remaining balance of the escrow account to the Company’s operating account. As a result, the balance of the SBA Loan was $0 as of September 30, 2021.

 

NOTE 6 - STOCKHOLDERS’ EQUITY

 

The Company’s certificate of incorporation authorizes the issuance of up to 681,000,000 shares of common stock and 10,000,000 shares of Series A convertible preferred stock, each with a par value of $0.001 per share. As of March 31, 2022, the Company had 87,560,647 shares of common stock, and no shares of preferred stock, outstanding.

 

Common Stock

 

During the six months ended March 31, 2022, the Company issued 4,633,336 shares of its common stock as set forth below. No preferred stock has been issued during this six-month period.

 

Beginning with the last quarter of the Company’s fiscal year ended September 30, 2021, the Company’s Board of Directors elected to receive one-half of the members’ quarterly compensation in shares of the Company’s common stock, instead of cash. At its April 2021 meeting, the Board of Directors also approved a one-time award of 100,000 shares of common stock to each director, subject to approval of the Company’s new Equity Incentive Compensation Plan by its stockholders. That approval was received at the Company’s annual meeting of stockholders in September 2021. As a result, the Company’s directors have received a total of 633,336 shares of the Company’s common stock through the one-time grant and three quarterly compensation payments discussed above. The Company issued the shares for the one-time awards and the fiscal year 2021 fourth quarter awards, totaling 411,112 shares, on January 13, 2022. The Company issued the shares for the fiscal year 2022 first quarter awards totaling 111,112 on January 31, 2022, and shares for the second quarter awards totaling 111,112 on March 28, 2022.

 

On July 23, 2021, the Company entered into a financial advisory and consulting agreement with Paulson Investment Company, LLC (“Paulson”). Pursuant to that agreement, Paulson will provide the following services at the Company’s request: (a) familiarize itself with the Company’s business, assets and financial condition; (b) assist the Company in developing strategic and financial objectives; (c) assist the Company in increasing its exposure in the software industry; (d) assist the Company in increasing its profile in the investment and financial community through introductions to analysts and potential investors, participation in investment conferences and exploitation of reasonably available media opportunities; (e) identify potentially attractive merger and acquisition opportunities; (f) review possible innovative financing opportunities and (g) render other financial advisory services as may be reasonably requested by the Company. The term of the agreement is four years from the date of the agreement, unless terminated earlier by either party as provided therein. As compensation for the services provided by Paulson under the agreement, on March 20, 2022, the Company issued a total of 4,000,000 shares of the Company’s common stock to Paulson and three of its employees. This was valued at $720,000 at the date of the consulting agreement. The contract amount was capitalized as deferred contract costs and is being amortized to expense straight-line over the 4- year service period.

 

Restricted Common Stock Units

 

On October 22, 2021, the Company entered into restricted stock unit award agreements with four employees and one contractor. The Company granted a total of 2,000,001 shares of restricted stock to these individuals. The restricted stock awards vest in three equal tranches on the next three anniversaries of the date of the applicable awards. The value of the shares of restricted stock was $260,000, based upon the then current market price of the Company’s common stock of $0.13 per share on the grant date. For the six months ended March 31, 2022, the Company recorded $51,568 in stock compensation expense related to these agreements.

 

NOTE 7 – SUBSEQUENT EVENTS

 

The Company does not have any subsequent events to report as of the date of this filing.

 

12
Table of Contents

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Certain statements in our Management’s Discussion and Analysis of Financial Condition and Results of Operations, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties that may cause actual results to differ materially from the forward-looking statements. A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is included in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2021, and elsewhere in this Current Report on Form 10-Q. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Overview

 

Through a licensing program, we have offered our customers the right to use our Polymorphic Encryption Core, (“PEC”), which is a secure, advanced polymorphic data-in-motion product. Recently, one licensee, Castle Shield, began to report early-stage product sales from its software tools that contain our PEC.

 

To supplement the legacy licensing program, we are building our own applications that we intend to sell directly to enterprises and managed security service providers (“MSSP”). On February 14, 2022, we announced the launch of Cipherloc Enclave, our first internally developed product, through a press release and the filing of a Current Report on Form 8-K.

 

Cipherloc Enclave is a micro-segmentation product designed as an easy-to-use platform designed for organizations that are seeking to control communication between devices and fully encrypt traffic between those devices. Enclave is designed to provide a simple and cost-effective solution, as compared to current complex cost-prohibitive solutions, which we believe require technical personnel to operate. Cipherloc Enclave is designed to make micro-segmentation available to everyone at a low cost, and with minimum technical administration.

 

Cipherloc’s Enclave platform will be available through a free plan or a fee per user plan, designed to fit the needs of the two types of end users of the platform. The free tier will give individuals the ability to use the platform for hobby and educational purposes. The paid tier will focus on business users, allowing them to have a more private experience that addresses security and optimization gaps that many companies face in today’s ever-changing technology environment.

 

We anticipate that our operating expenses for the next twelve months will require between $2.0 and $2.7 million of cash, which will come from the net proceeds we received from a private placement of our securities held between March 31, 2021, and April 16, 2021. We intend to manage our business such that our current cash reserves will allow us to reach positive cash flow from our operations, but we cannot assure you that will occur. Our proposed approach to managing our cash will initially emphasize demonstrating our products’ capabilities with early adopters of Cipherloc Enclave. We will follow those efforts with using our remaining cash to scale all of our functional areas, including product development, marketing, sales, customer support, and administration.

 

We intend to focus our product development efforts on building new software and services to work with our existing core technology, while continuing to support our existing licensees. These efforts will require more personnel, as well as more infrastructure. We expect the increase in product development activities will require approximately $600,000 of our cash over the next 12 months. We plan to build the infrastructure we need to perform these new functions on modern technology, with scale and reliability. We plan to utilize cloud services to provide our customers with an interface that modern software provides, but also an ease of use that we believe encryption technologies desperately need. We believe that, if we are able to build our infrastructure, as described above, we will have a competitive advantage over most other participants in our market.

 

We intend to have our sales and marketing efforts emphasize qualified lead generation, using very focused industry messaging and engagement. We plan to participate in relevant cybersecurity and quantum computing industry events. We have also formed a board of advisors designed to help us identify the correct product focus areas and market segmentation. This board of advisors includes professionals from cybersecurity, technology business development and software marketing. We estimate that the expenses we will incur for sales and marketing during the next fiscal year will range between $600,000 and $800,000.

 

We expect that we will have to increase administrative costs if we are successful in generating revenue and need to hire additional employees. Our administrative resources will have to be increased according to our demand to support our employees, increase accounting capacities, and expand our reporting and compliance capabilities. We expect that we will need additional personnel in our accounting and human resources functions to support these expected staff additions. We also plan to add software tools to help us manage our internal processes.

 

We expect that we will need to add customer support teams if and when potential customers adopt each of our product offerings. We project the costs of customer support for our fiscal year 2022 will likely range from $100,000 to $300,000. We believe that these funds will be used primarily for salaries and technology to support these efforts. These expenses will be reported as part of our cost of goods sold.

 

13
Table of Contents

 

Results of Operations

 

Three and Six Months Ended March 31, 2022, Versus Three and Six Months Ended March 31, 2021

 

Comparison of Results

 

Our revenue decreased to $251 for the three months ended March 31, 2022, from $6,667 for the three months ended March 31, 2021. This decrease was due to lower licensee revenue for the period compared to the prior fiscal year. Our revenue decreased from $15,417 for the six months ended March 31, 2021 to $251 for the six months ended March 31, 2022, primarily due to low licensing activity taking place during the six months ended March 31, 2022.

 

Our general and administrative expenses were $607,014 and $889,172, respectively, for the three months ended March 31, 2022, and 2021. General and administrative expenses decreased in fiscal 2022, primarily as a result of (i) $108,711 in headcount related costs, including payroll and travel costs (ii) a decrease in professional fees of $106,941, (iii) a decrease in rent expenses of $96,268, and, (iv) a decrease in legal of $81,384 as a result of the settlement of various litigations matters during 2021. The decrease in general and administrative expenses was partially offset by an increase of $45,000 in amortization of deferred costs related to the private placement fees we paid to the placement agent of the private placement of shares of our common stock in March and April of 2021 and increase in other expenses of $46,146 and an increase in board fees of $20,000.

 

Our general and administrative expenses were $1,076,030 and $1,550,864 for the six months ended March 31, 2022, and 2021, respectively. The decrease in general and administrative expenses in 2022 was primarily due to (i) a decrease in legal expenses of $163,870, (ii) a decrease in rent of $134,047, (iii) a decrease in professional fees of $127,067, (iv) a decrease in board fees of $120,000, and, (v) a decrease in headcount related costs, including payroll and travel costs, of $94,814, due to bonus payouts in the prior fiscal year. The decrease in general and administrative expenses were partially offset by an increase of $90,000 in amortization of deferred costs related to the private placement fees we paid to the placement agent of the private placement of shares of our common stock in March and April of 2021 and increases in other expenses of $75,144.

 

Our sales and marketing expenses were $52,375 and $31,250 for the three months ended March 31, 2022, and 2021, respectively. Our sales and marketing expenses increased in fiscal 2022 by $37,500 related to the sales consultant expense and $14,875 brand and website marketing costs, partially offset by a $31,250 decrease in headcount expense related to sales employees in 2021.

 

Our selling and marketing expenses were $105,768 and $56,250 for the six months ended March 31, 2022, and 2021, respectively. Our sales and marketing expenses increased in fiscal 2022 primarily as a result of (i) an increase in consultant expense of $75,000, and (ii) an increase in marketing related costs of $29,750, partially offset by a $55,232 decrease in headcount related costs incurred during 2021.

 

Our research and development expenses were $140,919 and $175,083 for the three months ended March 31, 2022, and 2021, respectively. Our research and development expense increased in fiscal 2021 primarily due to personnel related costs.

 

Our research and development expenses were $270,558 and $296,876 for the six months ended March 31, 2022 and 2021, respectively. Our research and development expenses decreased for the six-month period ended March 31, 2022 primarily as a result of a decrease in consulting related costs of $72,254, partially offset by an increase in payroll related expense of $45,937, both of which were the result of the spending reductions we initiated during the prior fiscal year.

 

We had a net loss of $800,057, or $0.01 per share, for the three months ended March 31, 2022, compared to a net loss of $1,088,838, or $0.04 per share, for the three months ended March 31, 2021. The year-over-year decrease in the net loss for the three months ended March 31, 2022, was primarily due to a decrease in operating expenses from the prior fiscal year. For the six months ended March 31, 2022, we had a net loss of $1,452,105, or $0.02 per share, compared to a net loss of $1,888,573 or $0.07 per share, for the six months ended March 31, 2021.

 

Liquidity and Capital Resources

 

We had an accumulated deficit of $72,982,996 as of March 31, 2022. We expect to incur expenses and generate continued operating losses until we can generate revenues sufficient to cover our expected ongoing expenses. On March 31, 2022, we had cash of $4,390,059, primarily representing proceeds of the private placement of shares of our common stock in March and April 2021.

 

As of March 31, 2022, we had working capital of $4,279,557, compared to working capital of $4,756,094 as of September 30, 2021.

 

Cash Flows

 

The following table summarizes, for the periods indicated, selected items in our condensed Statements of Cash Flows:

 

   Six Months Ended 
   March, 
   2022   2021 
Net cash provided by (used in):          
Operating activities  $(1,393,935)  $(898,950)
Investing activities  $   $ 
Financing activities  $   $5,447,964 

 

14
Table of Contents

 

Operating Activities

 

We used cash in operating activities in the amounts of $1,393,935 and $898,950 for the six months ended March 31, 2022, and March 31, 2021, respectively. Our uses of cash during the six months ended March 31, 2022, were mainly attributable to a net loss of $1,452,105, which was partially offset by $90,000 in amortization of deferred costs, $51,568 in stock compensation expense, and an increase in our net operating assets and liabilities of $83,398. The change in our net operating assets and liabilities was primarily due to an increase in accounts payable and accrued liabilities of $220,022, which was partially offset by a decrease in prepaid and other assets of $136,624.

 

Cash used in operating activities was $898,950 for the six months ended March 31, 2021. The uses of cash during the quarter ended March 31, 2021, were attributable to a net loss of $1,888,573, which was offset by a non-cash stock compensation expense of $79,655 and a decrease in net operating assets and liabilities of $909,968. The change in our net operating assets and liabilities was primarily due to a decrease in prepaid and other assets of $342,544 and an increase in accounts payable and accrued liabilities of $582,841, partially offset by a decrease in deferred revenue of $15,417.

 

Investing Activities

 

We had no cash used in investing activities for either of the six months ended March 31, 2022, or March 31, 2021.

 

Financing Activities

 

Cash provided by financing activities was $5,447,964 for the six months ended March 31, 2021. The Company sold certain securities pursuant to the Private Offering, described in Note 2 – New Equity Issuance, to the unaudited financial statements included above, and raised $5,497,964, net of issuance costs, partially offset by the cash used in relation to a lawsuit filed by the Company against James LeGanke, as Trustee of Carmel Trust II, which was settled for $50,000 in exchange for the return of 1,000,000 shares of Series A Preferred Stock and 127,500 shares of common stock to the Company.

 

Off-Balance Sheet Arrangements

 

We did not have any off-balance sheet arrangements, as defined under applicable SEC rules, during the periods presented, nor do we currently have any such arrangements.

 

Critical Accounting Policies and Estimates

 

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our management periodically evaluates the estimates and judgments made. Management bases its estimates and judgments on historical experience and on various factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates as a result of different assumptions or conditions.

 

See Note 4 of the unaudited financial statements included in “Part I—Item 1. Financial Statements,” above, for a discussion of our significant accounting policies.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

As required by Rule 13a-15(b) of the Exchange Act, we have evaluated, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure, and is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report, at the reasonable assurance level.

 

15
Table of Contents

 

Changes in Internal Control over Financial Reporting

 

During the six months ended March 31, 2022, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, including any corrective actions regarding significant deficiencies and material weaknesses.

 

Limitations on Effectiveness of Controls and Procedures

 

In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that our management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business.

 

Such current litigation or other legal proceedings are described in, and incorporated by reference into, this “Part II - Item 1. Legal Proceedings” from “Part I - Item 1. Financial Statements” in the notes to financial statements in “Litigation” in Note 5 – Commitments and Contingencies. We believe that the resolution of currently pending matters will not individually or in the aggregate have a material adverse effect on our financial condition or results of operations. However, assessment of current litigation or other legal claims could change in light of the discovery of facts not presently known to us, or by decisions of judges, juries or other finders of fact, which are not in accord with our evaluation of the possible liability or outcome of such litigation or claims.

 

Additionally, the outcome of litigation is inherently uncertain. If one or more legal matters are resolved against us in a reporting period for amounts in excess of our expectations, our financial condition and operating results for that reporting period could be materially adversely affected.

 

ITEM 1A. RISK FACTORS

 

There have been no material changes from the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended September 30, 2021, filed with the Commission on December 21, 2021 (the “Form 10-K”), under the heading “Risk Factors.

 

16
Table of Contents

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Sales of Securities

 

There were no sales of unregistered securities of the Company during the quarter ended March 31, 2022, and from the period from September 30, 2021 to the filing date of this report, which have not previously been disclosed in the Company’s Quarterly Reports on Form 10-Q or in a Current Report on Form 8-K.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINING SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

        Incorporated by Reference    

Exhibit

No.

  Description   Form   File No.   Exhibit  

Filing

Date

  Filed/Furnished Herewith
                         
31.1*   Certification of Principal Executive Officer Pursuant to the Securities Exchange Act of 1934, Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                   X
31.2*   Certification of Principal Financial Officer Pursuant to the Securities Exchange Act of 1934, Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                   X
32.1**   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                   X
32.2**   Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                   X
101.INS*   Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. XBRL Instance Document                   X
101.SCH*   Inline XBRL Taxonomy Extension Schema Document XBRL Taxonomy Extension Schema Document                   X
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document XBRL Taxonomy Extension Calculation Linkbase Document                   X
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document XBRL Taxonomy Extension Definition Linkbase Document                   X
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document XBRL Taxonomy Extension Label Linkbase Document                   X
101.LAB*   Inline XBRL Taxonomy Extension Presentation Linkbase Document XBRL Taxonomy Extension Presentation Linkbase Document                   X
104*   Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set                   X

 

* Filed herewith.

 

17
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Cipherloc Corporation
   
Date: May 13, 2022 By: /s/ David Chasteen
    David Chasteen
   

Chief Executive Officer

(Principal Executive Officer)

 

  Cipherloc Corporation
   
Date: May 13, 2022 By: /s/ Ryan Polk
    Ryan Polk
   

Chief Financial Officer

(Principal Accounting/Financial Officer)

 

18